Browsing Tag
PAXLOVID
8 posts
Coronavirus is still evolving: The essential guide to symptoms, treatment options, and protection
Explore this complete guide on coronavirus symptoms, treatment options, and prevention tips to stay protected every year.
Pfizer Q3 2025 earnings beat forecasts as non-COVID drug sales lift margins and EPS guidance
Find out how Pfizer beat Q3 2025 earnings forecasts and raised full-year EPS guidance as non-COVID drugs and cost savings drove profit growth.
Pfizer beats Q2 2025 earnings expectations and raises profit forecast, but long-term growth questions persist
Pfizer beats Q2 2025 estimates and raises profit guidance, but patent expirations and pricing pressures keep long-term growth questions on the table.
COVID-19 still killing 300 Americans weekly in 2025: Low vaccine uptake blamed
More than 300 Americans still die from COVID weekly. Find out why vaccine uptake, variant risks, and treatment gaps keep the toll high in 2025.
Pfizer stuns Wall Street with booming Q3 earnings and new guidance boost
Pfizer Inc. delivered a financial jolt in its third quarter of 2024, surpassing Wall Street’s expectations and raising…
Pfizer gets PAXLOVID FDA approval for COVID-19 in high-risk adults
Pfizer has obtained approval for PAXLOVID, an oral combination therapy of nirmatrelvir tablets and ritonavir tablets, from the…
Torrent Pharmaceuticals gets rights to generic of Pfizer’s oral Covid-19 treatment
Torrent Pharmaceuticals has entered into a licensing agreement with Medicine Patent Pool (MPP) for manufacturing and commercializing the…
SMS Pharmaceuticals gets license to Pfizer Covid‐19 drug nirmatrelvir
SMS Pharmaceuticals has secured a non‐exclusive license via the Medicines Patent Pool (MPP) for manufacturing nirmatrelvir, an oral…